Utility of Targeted, Amplicon-Based Deep Sequencing To Detect Resistance to First-Line Tuberculosis Drugs in Botswana

DOI: 10.1128/AAC.00982-19

Article Information

DOI

PubMed

Published By

History

^aSue & Bill Gross School of Nursing, University of California Irvine, Irvine, California, USA
^bBotswana-UPenn Partnership, Gaborone, Botswana
^cDepartment of Infectious Disease, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
^dTranslational Genomics Research Institute, Flagstaff, Arizona, USA
^eNRF-DST Centre of Excellence for Biomedical Tuberculosis Research, Tygerberg, South Africa
^fSouth African Medical Research Council Centre for Tuberculosis Research, Tygerberg, South Africa
^gDivision of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
^hDepartment of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Address correspondence to Sanghyuk S. Shin, ssshin2{at}uci.edu.
N.M.Z. and S.S.S. contributed equally to this work.
Citation Wang Q, Modongo C, Allender C, Engelthaler DM, Warren RM, Zetola NM, Shin SS. 2019. Utility of targeted, amplicon-based deep sequencing to detect resistance to first-line tuberculosis drugs in Botswana. Antimicrob Agents Chemother 63:e00982-19. https://doi.org/10.1128/AAC.00982-19.

Rendering graph...